Business

A new research report titled "Global Markets for Asthma & COPD Drugs" from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38 billion in 2012 and just over $47 billion in 2017. The report predicts that asthma drug sales alone will reach $20.2 billion in 2017, up from $15.3 … [Read more...] about Research firm predicts global asthma and COPD market will reach $47 billion by 2017

Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as a substitute for the banned CFC Primatene Mist inhaler. According to the company, the product will be available at … [Read more...] about Nephron announces launch of OTC asthma inhalation product

Watson Pharmaceuticals has launched a generic levalbuterol inhalation solution, an authorized version of Sunovion's Xopenex for the treatment of asthma. Shipments will begin immediately. The company cites IMS Health data saying that sales of Xopenex for the past 12 months were approximately $474 million. Read the Watson press release. … [Read more...] about Watson launches authorized generic levalbuterol inhalation solution

According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to invest approximately £5 million to renovate some of the remaining buildings. In March 2011, Novartis announced significant personnel reductions at the site … [Read more...] about Novartis reaffirms that respiratory research is to remain in Horsham, UK

GE Capital Healthcare Financial Services has announced today that it is providing $7.5 million in financing to Trimel Pharmaceuticals for Phase 2 and 3 clinical development of several OINDPs. Trimel's pipeline includes asthma and allergic rhinitis therapies based on its Trivair dry powder inhaler technology and male and female sexual dysfunction therapies based on its … [Read more...] about $7.5 million in new financing for Trimel Pharmaceuticals

Israeli biopharmaceutical company Kamada will receive milestone payments of $60 million as part of a 12-year distribution agreement with Chiesi Farmaceutici for Kamada's inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH). Chiesi will distribute the inhalation solution in Europe, Turkey and former CIS countries. Kamada expects … [Read more...] about Chiesi to distribute Kamada’s inhaled AAT

According to Insmed, the US Patent and Trademark Office has issued the company a second composition of matter patent for Arikace liposomal amikacin for inhalation, US Patent No. 8,226,975. Insmed is developing the product for the treatment of cystic fibrosis and non-tuberculous mycobacteria (NTM). The company recently decided to defer a Phase 3 study of Arikace in the … [Read more...] about Insmed gets additional patent for Arikace

Aptar Pharma has announced that the Zetonna nasal aerosol device recently launched in the US includes a customized Aptar Landmark dose indicator, the result of a six-year collaboration with Sunovion. Zetonna is delivered by a pressurized metered dose inhaler, and the FDA recommends that all new pMDI products have an integrated dose counter. Aptar Pharma … [Read more...] about Aptar dose indicator on newly-approved nasal aerosol

According to a report in The Business Standard, Novartis India has announced an agreement with Lupin to sell the Onbrez indacaterol inhalation capsules for the treatment of COPD in India. The newspaper cited "an industry source" for the information. The article says that the capsules would be available in two doses, 150 mg and 300 mg. Few other details were … [Read more...] about Lupin to market Onbrez inhalation capsules in India